Next Gen Immuno-Oncology Congress

Opening remarks from the Chairman

Frank Borriello, CEO, Alloplex Biotherapeutics

Keynote: Mutations in the IL-7 receptor driving acute lymphoblastic leukemia

Scott Durum, Head, Cytokines and Immunity, NIH

Natural single domain antibodies as potential alternatives to monoclonal antibodies in the next generation immunotherapy

Rajesh Singh, Laboratory Director, Abzyme Therapeutics

Screening the Membrane Proteome to Determine Antibody Specificity and Discover New Immunomodulatory Targets

Tabb Sullivan, Senior Scientist, Project Leader, Integral Molecular

Morning Refreshments and Poster Presentations | One-to-One Networking Meetings

Targeted Antibodies and Combinations

Learnings from the successful Cancer Immunotherapy Combinations and Bispecifics

Rakesh Dixit, CEO, Bionavigen

Human Cell Culture: The Role of In Vitro models in Cancer Immunotherapy Development

Melissa Olekson, Scientific Support Specialist, PromoCell

Therapeutic targeting of the tumor microenvironment

ex vivo PBMC Activation of Antitumor Activity Offers Accelerated Path to Clinical Application

Frank Borriello, CEO, Alloplex Biotherapeutics

Lunch and Poster Presentations | One-to-One Networking Meetings

New Antibody Formats and Developments in CAR-T Cell Therapy

Biomarkers Associated with Clinical Outcomes in ZUMA-1 Supporting Approval of Yescarta

Vicki Plaks, Translational Lead, Principal Scientist, Translational Sciences, Kite Pharma

Improving the Safety and Efficacy Profile of CAR-T: GM-CSF Neutralization with Lenzilumab

Next-generation gene editing technology for allogeneic T cell therapeutics

Megan van Overbeek, Associate Director of Functional Genomics, Caribou Biosciences

Evening Refreshments and Poster Presentations | One-to-One Networking Meetings

“RubrYc Therapeutics: Overcoming Immunodominance to Discover Next Gen Biotherapeutics”

Matt Greving, Co-Founder & VP, Technology, RubrYc Therapeutics Inc.

Closing remarks from the Chairman

Cocktail Reception | End of Day 1

Opening remarks from the Chairman

Shahram Salek-Ardakani, Chief Scientific Officer, Janux Therapeutics

Keynote: Defining T Cell States Associated with Response to Combination Immunotherapy

Shahram Salek-Ardakani, Chief Scientific Officer, Janux Therapeutics

Breast Cancer Immunotherapy: Novel Combinations of Bria-IMT™ with Checkpoint Inhibitors

William Williams, President, CEO, Briacell Therapeutics Corporation

Accelerating Therapeutic Antibody Discovery and Development with Innovative Humanized Mouse Models

Qingcong Lin, Senior Vice President, CEO, Biocytogen Boston Corporation

Pre-clinical & Translational Immuno-Oncology Developments

Reversing trastuzumab resistance in HER2+ breast cancer

RJ Tesi, CEO, CMO, INmune Bio Inc.

Humanized Mouse Models for Immuno-Oncology Research

Sebastien Tabruyn, Chief Scientific Officer, Transcure Bioservices

Preserving CTLA4 function to make a better and safer anti-CTLA4 antibody

Pan Zheng, Professor, University of Maryland School of Medicine

New Immune Checkpoints for Immunotherapy

Clinical development of GITR based immunotherapies

Girish Naik, Medical Director, Leap Therapeutics

B cells in the human tumor microenvironment

Tullia Bruno, Assistant Professor, Immunology, University of Pittsburgh

Evening Refreshments and Poster Presentations | One-to-One Networking Meetings

Break out Session: Future of Biologics in Immune Checkpoint therapy

Closing remarks from the Chairman

Opening remarks from the Chairman

Emmanuel Normant, Vice President, Preclinical Sciences, TG Therapeutics

New Antibodies Development and Tumor Microenvironment

Keynote: Anti PD-! Antibodies are Transforming Cancer Care both as Mono- and Combination Therapy

Roy Baynes, Executive Vice President, Chief Medical Officer, Eikon Therapeutics

Combinations of antibodies and small molecules in the Immuno-Oncology world: A TG Therapeutics perspective

Emmanuel Normant, Vice President, Preclinical Sciences, TG Therapeutics

Targeting Immunosuppressive Sialoglycans in the Tumor Microenvironment Using A Novel Therapeutic Modality EAGLE

Li Peng, Senior Vice President, Palleon Pharma

Morning Refreshments and Poster Presentations | One-to-One Networking Meetings

Novel T cell engaging bispecific antibodies for cancer immunotherapy

Thomas Tan, Vice President, Immunology, Elstar Therapeutics

B7-H3, an attractive target of antibody-based immunotherapy

Soldano Ferrone, Professor of Surgery, Massachusetts General Hospital, Harvard Medical School

Comparing immunological marker signatures across various cancer types

Natalie Russi, Scientific Project Manager, Nebion

End of Conference

Closing remarks from the Chairman

Opening remarks from the Chairman

Stefan Glueck, Senior Vice President, Global Medical Affairs, Celgene

Personalized Immunotherapy and T-Cell Therapies

Keynote: Tumor Inflammatory Signature

Carl Morrison, President, Chief Medical Officer, OmniSeq

Development of effective immunotherapeutic combinations with antitumor activities

Joost Oppenheim, Head, Cellular Immunology, NIH

Update on ICI data in early and metastatic breast cancer

Stefan Glueck, Senior Vice President, Global Medical Affairs, Celgene

End of Conference

Closing remarks from the Chairman